Amazon just crashed the weight-loss party

Amazon (AMZN) wants a piece of the weight-loss market.

The company is rolling out a new weight loss program through Amazon One Medical that makes it easier to access GLP-1 drugs like Wegovy and Zepbound.

In short… Amazon is turning weight loss into a subscription service.

Investors noticed. Stocks tied to the obesity drugs dropped almost instantly. Novo Nordisk (NVO) and Eli Lilly (LLY) dropped by around 4% each.

This is what happens when the world’s best logistics machine targets healthcare… and inserts itself between you and your doctor.

If Amazon can do to pharmacies what it did to retail, it could reshape who wins in one of the most important medical markets of this decade.

The award for the most disruptive drug goes to…

Semaglutide—aka Ozempic—wins my vote.

In the 1990s, scientists studying the Gila monster discovered it can survive on one meal per month. They created a synthetic version of this lizard’s spit and turned it into the most important drug of the 21st century: semaglutide.

First, we discovered that semaglutide treats diabetes. Then, we found the drug—best known as Ozempic—melts fat off waistlines.

In a slew of recent trials, doctors are now discovering this “miracle in a syringe” also:

• Treats Alzheimer’s disease.

• Reduces heart attacks and strokes.

• Suppresses addiction.

• Lowers the risk of developing kidney, pancreatic, ovarian, liver, and colorectal cancers.

Since launch, Novo Nordisk has sold tens of millions of prescriptions globally, with demand still outstripping supply in many markets. At this pace, a trillion dollars in cumulative sales doesn’t sound far-fetched.

I’m a big believer in staying fit and healthy the old-school way. Get out of breath at least every other day and relax on the sugar.

But I’m all for Ozempic. I know so many people who’ve shed weight taking it. It was the “kick” they needed to start living healthier.

But WeightWatchers (WW) has been the biggest loser from Ozempic (no pun intended).

Why bother going to group meetings and fight cravings when you can just take a fat-killing jab instead?

Novo’s stock surged after Ozempic won U.S. approval in December 2017.

Though much of that Wegovy-era run had been erased by early 2026.

Eli Lilly (LLY), meanwhile, climbed roughly 1,200% from late 2017 to its November 2025 peak.

Those are the kinds of gains disruptors can hand out.

Disruption is the most powerful force in markets. It’s ruthless. It doesn’t care how big you are or how long you’ve been on top.

Blockbuster dominated video rentals until Netflix (NFLX).

Nokia led mobile phones until Apple (AAPL) took over with the iPhone.

Amazon (AMZN) wiped out iconic retailers like Toys “R” Us and even the mighty Sears.

The same playbook repeats. A disruptor shows up. The old giant stumbles. The disruptor claims the spoils and sees its stock surge.

2025 may go down as the year America started to seriously push back against obesity.

That’s what future historians will write.

That may sound bold. But the trend is getting harder to ignore.

A late-2025 KFF poll found that 12% of U.S. adults say they are currently taking a GLP-1 drug, up from 6% in May 2024. At the same time, newer CDC and public health reports suggest obesity rates are no longer rising the way they were for years and may finally be starting to level off.

Coincidence?

Maybe Ozempic will have a bigger real-world impact than artificial intelligence.

In many countries in Europe, you basically can’t get semaglutide unless you’re morbidly obese. So a black markets for Ozempic have emerged. When law-abiding, God-fearing citizens are turning to the black market for your product, you know you’re onto something.

Right now, taking Ozempic requires jabbing yourself with a needle. Inconvenient.

Imagine how many more people will try these drugs now that the needle is no longer the only option.

That future is already here. Novo Nordisk now has an approved weight-loss pill on the market in the U.S. and Eli Lilly has its own oral GLP-1 pill, orforglipron, moving through late-stage development and commercialization steps.

Novo hasn’t traded this cheap in years.

The stock is down roughly 60–70% from its 2024 highs, with some stretches even worse as competition fears took over the narrative.

Investors are dumping the stock on concerns that Eli Lilly is catching up… and in some cases pulling ahead.

But zoom out.

Novo Nordisk is still one of the most profitable drug companies on the planet. It grew sales 10% in 2025 and continues to throw off billions in cash.

Yes, competition is real.

Novo’s market share has slipped as new drugs enter the space. But its flagship products — Ozempic and Wegovy — are still household names.

That kind of brand power doesn’t disappear overnight.

And the market itself is still massive.

GLP-1 drugs are expected to grow into a $100B+ market over the next decade, with demand still outpacing supply in many regions.

So yes… the story has changed.

Growth is slowing. Competition is rising. The easy money has been made.

But if you believe obesity drugs are one of the defining health trends of this decade, this pullback looks less like a buying opportunity.